Application of gene therapy for Parkinson's disease: nonhuman primate experience.
Bankiewicz
K S
KS
Somatix Therapy Corporation, Alameda, California 94501, USA.
Bringas
J R
JR
McLaughlin
W
W
Pivirotto
P
P
Hundal
R
R
Yang
B
B
Emborg
M E
ME
Nagy
D
D
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D001812:Blood-Brain Barrier; D001921:Brain / Q000378:metabolism; D002421:Caudate Nucleus / Q000201:enzymology; D003342:Corpus Striatum / Q000201:enzymology; D018076:DNA, Complementary; D000229:Dependovirus; D015870:Gene Expression; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D000882:Haplorhini; D006801:Humans; D010300:Parkinson Disease / Q000628:therapy*; D010302:Parkinson Disease, Secondary / Q000628:therapy; D013997:Time Factors; D014182:Transplantation, Autologous; D014446:Tyrosine 3-Monooxygenase / Q000096:biosynthesis / Q000235:genetics*; D001616:beta-Galactosidase / Q000096:biosynthesis
D018076:DNA, Complementary; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D014446:Tyrosine 3-Monooxygenase; D001616:beta-Galactosidase